Celsius Holdings, Inc. Common Stock
CELH
$28.02
-1.13%
Celsius Holdings operates in the energy drink subsegment of the global non-alcoholic beverage market, generating approximately 95% of its revenue in North America through three owned brands: Celsius, Alani Nu, and Rockstar Energy. The company outsources manufacturing and packaging to third-party co-packers and relies on PepsiCo for distribution, a relationship cemented by PepsiCo's convertible preferred equity investments in 2022 and 2025 that give the beverage giant an 11% stake. Celsius has evolved from a single-brand disruptor into a multi-brand platform following the transformative Alani Nu acquisition, which has become the primary growth engine offsetting deceleration in the flagship Celsius brand. The current investor debate centers on whether the company can sustain its premium growth trajectory amid intensifying competition, a Q2 2026 earnings miss that sent shares tumbling 18% in a single day, and declining flagship brand sales, all set against a backdrop of a stock that has fallen roughly 49% from its 52-week high and trades at a low forward valuation that bulls argue already discounts substantial pessimism.…
CELH
Celsius Holdings, Inc. Common Stock
$28.02
Related headlines
Investment Opinion: Should I buy CELH Today?
The synthesized recommendation is a Hold. The core thesis is that Celsius offers a compelling growth story through Alani Nu, but near-term execution risks and declining flagship sales create too much uncertainty to justify a Buy at this time. The analyst consensus rating of 1.75 (buy) and average target price of $42.29 imply 50.9% upside, but the wide target range of $26 to $64 reflects significant disagreement about the company's trajectory. The stock's 49% decline from its 52-week high has created a low forward valuation, but the market is rightly concerned about the sustainability of growth.
Supporting evidence for a Hold includes the forward PE of 16.33x, which is below the consumer defensive sector average of 20-25x, suggesting the stock is inexpensive if earnings estimates are met. Revenue growth of 137.68% year-over-year in Q1 2026 is impressive, but it is largely acquisition-driven, and organic growth is uncertain. The gross margin compression from 52.35% to 48.31% is a red flag, and free cash flow, while positive at $292.8 million TTM, is highly uneven. The balance sheet is strong with low debt and $549.2 million in cash, providing a cushion. The implied upside to the average analyst target is substantial, but the low target of $26.00 is only 7% below the current price, indicating limited downside protection.
The biggest risks that could invalidate the thesis are a continued decline in flagship Celsius brand sales, further gross margin compression, and a failure to achieve the forward EPS estimate of $2.19. The rating would upgrade to Buy if the stock stabilizes above $30 and gross margins recover above 50%, or if Q3 2026 earnings show organic growth in the flagship brand. It would downgrade to Sell if revenue growth decelerates below 20% or if the stock breaks below the 52-week low of $23.56. Relative to its history, the stock is undervalued, but relative to peers, it is fairly valued given its execution risks. The valuation verdict is fairly valued with a slight bias toward undervaluation if estimates are met.
Sign up to view all
CELH 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. The stock's low forward valuation and high analyst upside are attractive, but the risks of declining flagship sales, margin compression, and execution uncertainty are significant. The base case (50% probability) assumes moderate growth and a stock price of $35-45, while the bull and bear cases are equally weighted at 25% each. I would upgrade to bullish if the company demonstrates organic growth in the flagship brand and gross margin recovery, and downgrade to bearish if revenue growth decelerates below 20% or if the stock breaks below $23.56. The key tension is whether Alani Nu's momentum can offset flagship weakness and drive sustainable profitability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celsius Holdings, Inc. Common Stock's 12-month outlook, with a consensus price target around $42.29 and implied upside of +50.9% versus the current price.
Average Target
$42.29
0 analysts
Implied Upside
+50.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $64
Analyst target range
Celsius is covered by 21 analysts with a consensus recommendation of "buy" (recommendation mean of 1.75 on a scale where 1 is strong buy and 5 is strong sell), reflecting a generally bullish but not overwhelmingly enthusiastic stance. The average price target of $42.29 implies approximately 50.9% upside from the current price of $28.02, a substantial gap that suggests analysts believe the recent selloff has been overdone relative to fundamental value. The consensus leans bullish, with the recommendation mean of 1.75 indicating that the majority of covering analysts rate the stock a buy or overweight, and the estimated revenue average of $4.04 billion for the forward period implies roughly 30% growth from the trailing revenue run-rate, supporting the constructive outlook.
The target price range spans from a low of $26.00 to a high of $64.00, a spread of $38.00 or 146% of the current price, which signals significant disagreement among analysts about the company's trajectory. The high target of $64.00 implies roughly 128% upside and would require a combination of multiple expansion back toward historical levels, successful Alani Nu integration driving sustained revenue growth, and a recovery in the flagship Celsius brand; the low target of $26.00 implies about 7% downside and prices in continued market share losses, margin compression, and the risk that forward EPS estimates prove unachievable. The institutional ratings data shows a cluster of reiterations at Buy/Overweight from major firms including Citigroup, Needham, UBS, Roth Capital, B of A Securities, Morgan Stanley, BNP Paribas, and JP Morgan between May and July 2026, with no downgrades visible in the data, suggesting that despite the stock's poor price performance, sell-side analysts have not capitulated on their constructive views. The wide target spread combined with the recent 18% single-day drop on Q2 earnings indicates high uncertainty, and the fact that the average target has not been revised downward despite the stock's decline may reflect either analyst conviction or a lag in updating estimates following the disappointing quarter.
Bulls vs Bears: CELH Investment Factors
The bear case currently has stronger evidence due to the recent Q2 2026 earnings miss, declining flagship brand sales, and gross margin compression, which have driven the stock down 49% from its 52-week high. However, the bull case is supported by the transformative Alani Nu acquisition, which drove 137.68% revenue growth, a low forward PE of 16.33x, and a consensus buy rating with 50.9% upside to the average analyst target. The most important tension is whether the forward EPS estimate of $2.19 is achievable; if Alani Nu's momentum can offset flagship weakness and margins stabilize, the stock is undervalued, but if estimates prove optimistic, further downside is likely. The market is pricing in significant pessimism, but the risk of a value trap remains high given execution risks.
Bullish
- Alani Nu Drives 138% Revenue Growth: Q1 2026 revenue reached $782.6 million, up 137.68% year-over-year from $329.3 million in Q1 2025, driven by the transformative Alani Nu acquisition. This growth rate is exceptional for a consumer staples company and demonstrates the success of the multi-brand strategy.
- Forward PE of 16.3x Signals Deep Value: The forward PE of 16.33x is well below the trailing PE of 182.96x and represents a significant discount to the consumer defensive sector average of 20-25x. This implies the market expects EPS to grow from $0.01 to $2.19, a target that, if achieved, would make the stock inexpensive.
- Analyst Consensus Buy with 51% Upside: 21 analysts rate the stock a buy with a recommendation mean of 1.75, and the average price target of $42.29 implies 50.9% upside from the current price of $28.02. The high target of $64.00 suggests even greater potential if execution improves.
- Strong Balance Sheet and Cash Flow: Debt-to-equity is a low 0.228 and the current ratio is 1.679, providing ample liquidity. Free cash flow TTM is $292.8 million, and the company holds $549.2 million in cash, giving it flexibility to invest in growth or weather downturns.
Bearish
- Flagship Celsius Brand Sales Declining: Recent news highlights declining flagship Celsius brand sales, which threatens the sustainability of the growth narrative. The Q2 2026 earnings miss and 18% single-day drop underscore the market's concern about the core brand's health.
- Gross Margin Compression: Gross margin fell to 48.31% in Q1 2026 from 52.35% in Q1 2025, a 404 basis point decline. This compression suggests promotional intensity, input cost inflation, or a mix shift toward lower-margin products, which could pressure profitability.
- Earnings Volatility and Negative PEG: The company reported a net loss of -$61.0 million in Q3 2025 and has a negative PEG ratio of -4.01 due to trailing earnings volatility. This inconsistency makes it difficult to value the stock on current earnings.
- Intense Competition and PepsiCo Dependency: Celsius faces intense competition from Monster and other energy drink players, and relies on PepsiCo for distribution. PepsiCo's own North America volume declines could impact Celsius's shelf space and growth.
CELH Technical Analysis
Celsius is entrenched in a sustained downtrend, with the stock down 49.23% over the past year and 41.32% year-to-date, dramatically underperforming the S&P 500's +15.01% 1-year and +11.70% YTD returns. At the current price of $28.02, the stock sits at just 10.3% of its 52-week range (52-week low of $23.56, 52-week high of $66.74), a positioning that reflects persistent selling pressure rather than a value opportunity, though it does place the shares in deeply oversold territory relative to their historical trading band. The maximum drawdown of -63.35% underscores the severity of the decline from peak levels, and with the stock hovering only about 19% above its 52-week low, the risk of testing or breaching that floor remains a live concern for holders.
Short-term momentum remains decisively negative and is diverging bearishly from an already weak longer-term trend. The stock is down 13.14% over the past month and 9.03% over the past three months, with the 1-month decline steeper than the 3-month decline, indicating that selling pressure has actually accelerated in recent weeks rather than stabilized. This acceleration is confirmed by the relative strength readings: -12.18% versus SPY over 1 month and -11.03% over 3 months, meaning Celsius is not merely falling but is losing ground to the broader market at an increasing rate. The 6-month change of -32.50% and relative strength of -49.94% versus SPY further illustrate a stock in a persistent relative downtrend with no evidence of near-term mean reversion, and the most recent price action — sliding from $35.34 on August 25 to $28.02 by September 18 — shows a sharp, uninterrupted leg lower.
Key technical levels are clearly defined by the 52-week range: support rests at the 52-week low of $23.56, roughly 16% below the current price, while resistance is anchored at the 52-week high of $66.74, an imposing 138% above current levels. A breakdown below $23.56 would signal capitulation and likely open the door to new multi-year lows, potentially triggering further momentum-driven selling, whereas a sustained breakout above even intermediate resistance in the low-to-mid $30s would be the first meaningful sign of trend stabilization. The stock's beta of 0.922 indicates slightly lower volatility than the broader market, which is somewhat surprising given the magnitude of its drawdown, but it suggests that position sizing can be managed with standard risk parameters; however, the elevated short ratio of 2.24 days-to-cover and the recent 18% single-day drop on Q2 earnings highlight that event-driven volatility remains a significant risk regardless of the beta reading.
Beta
0.92
0.92x market volatility
Max Drawdown
-63.4%
Largest decline past year
52-Week Range
$24-$67
Price range past year
Annual Return
-49.2%
Cumulative gain past year
| Period | CELH Return | S&P 500 |
|---|---|---|
| 1m | -13.1% | -0.5% |
| 3m | -9.0% | +2.3% |
| 6m | -32.5% | +16.6% |
| 1y | -49.2% | +14.8% |
| ytd | -41.3% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELH Fundamental Analysis
Celsius's revenue trajectory has been transformed by the Alani Nu acquisition, with Q1 2026 revenue reaching $782.6 million, representing 137.68% year-over-year growth from $329.3 million in Q1 2025, though this growth is heavily acquisition-driven rather than organic. The multi-quarter trend shows revenue stepping up from $332.2 million in Q4 2024 to $739.3 million in Q2 2025, $725.1 million in Q3 2025, $721.6 million in Q4 2025, and $782.6 million in Q1 2026, indicating that the business has stabilized around the $720-780 million quarterly range following the Alani Nu integration. However, the most recent news highlights declining flagship Celsius brand sales and a Q2 2026 earnings miss, suggesting that the headline growth masks underlying weakness in the core brand that could pressure future revenue if Alani Nu's momentum decelerates. The revenue segment data shows a single reportable segment of $782.6 million, reflecting the company's concentrated North American footprint and limited diversification.
Profitability has been volatile but is currently solid, with Q1 2026 net income of $110.1 million on a 14.07% net margin and a gross margin of 48.31%, down from the 52.35% gross margin in Q1 2025 but up from the 47.37% in Q4 2025. The quarterly earnings history reveals significant swings: Q3 2025 posted a net loss of -$61.0 million (-8.41% net margin) driven by a $452.3 million SG&A spike, while Q2 2025 delivered $99.9 million in net income at a 13.51% margin and Q4 2025 generated $24.7 million at a 3.43% margin. The gross margin compression from 52.35% to 48.31% year-over-year is a concerning trend that suggests either promotional intensity, input cost inflation, or a mix shift toward lower-margin products, and the operating margin of 18.63% (TTM) versus 17.76% in Q1 2026 indicates some quarterly variability. For the non-alcoholic beverage industry, a ~48% gross margin is respectable but below the levels typically enjoyed by established players like Monster Beverage, reflecting Celsius's still-scaling cost structure and reliance on third-party co-packers.
Celsius maintains a healthy balance sheet with a debt-to-equity ratio of just 0.228 and a current ratio of 1.679, providing ample liquidity to fund operations and growth initiatives. Free cash flow on a trailing twelve-month basis stands at $292.8 million, though the quarterly pattern is highly uneven: Q1 2026 generated $65.8 million in FCF, Q4 2025 burned -$130.0 million, Q3 2025 produced $321.5 million, and Q2 2025 generated $35.5 million, reflecting significant working capital swings tied to inventory and receivables management. The company holds $549.2 million in cash as of Q1 2026, down from $932.5 million at Q3 2025, largely due to the Alani Nu acquisition and debt repayment of $200.3 million in Q4 2025. Return on equity is a modest 3.67% and ROA is 8.85%, both depressed by the large equity base and acquisition-related amortization, but the low leverage and substantial cash position suggest the company has the financial flexibility to weather near-term earnings volatility without external financing pressure.
Quarterly Revenue
$782615000.0B
2026-03
Revenue YoY Growth
+137.7%
YoY Comparison
Gross Margin
48.3%
Latest Quarter
Free Cash Flow
$292759000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELH Overvalued?
Because Celsius reported positive trailing net income (EPS of $0.01), the PE ratio is the appropriate primary valuation metric, and the trailing PE of 182.96x appears extraordinarily rich at first glance. However, the forward PE of 16.33x tells a dramatically different story, implying that the market expects earnings to grow roughly 11-fold over the next twelve months, driven by the analyst consensus EPS estimate of $2.19 for the forward period versus the trailing $0.01. This enormous gap between trailing and forward multiples reflects the distortion from acquisition-related charges and integration costs in the trailing figures, and the forward PE of 16.33x is actually quite reasonable for a consumer staples growth company, suggesting the market is pricing in a normalization of earnings rather than speculative growth.
On a price-to-sales basis, Celsius trades at 4.28x TTM sales and 2.95x EV/Sales, which compares favorably to its own historical PS ratios that ranged from 11.65x in Q1 2026 to as high as 54.01x in Q1 2024, indicating a massive de-rating over the past two years. The PEG ratio of -4.01 is not meaningful given the negative earnings growth rate in the trailing period, but the forward PE of 16.33x against an estimated EPS growth rate from $0.01 to $2.19 implies a PEG well below 1.0 on a forward basis, which would suggest undervaluation if the estimates prove accurate. Relative to the broader consumer defensive sector, where established beverage companies often trade at 20-25x forward earnings, Celsius's 16.33x forward PE represents a discount of roughly 20-35%, though this discount is arguably justified by the company's smaller scale, single-segment concentration, and the execution risk embedded in the aggressive forward estimates.
The historical ratio data reveals that Celsius's valuation has compressed dramatically from its growth-stock heyday: the PS ratio has fallen from 54.01x in Q1 2024 to 4.28x currently, and the PB ratio has declined from 16.52x in Q1 2024 to 3.66x now. The current PE of 182.96x is near the high end of its historical range, but this is entirely due to the depressed trailing earnings base rather than multiple expansion, and the forward PE of 16.33x is likely near multi-year lows for the stock. This compression suggests the market has fully repriced Celsius from a high-growth momentum name to a more mature, value-oriented profile, and the key question is whether the forward earnings estimates of $2.19 per share are achievable; if they are, the stock is inexpensive, but if they prove optimistic given declining flagship sales and competitive pressures, the current valuation could still be vulnerable.
PE
183.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~153x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
54.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's gross margin declined from 52.35% in Q1 2025 to 48.31% in Q1 2026, a 404 basis point compression that could continue if promotional activity increases or input costs rise. Earnings volatility is extreme, with a net loss of -$61.0 million in Q3 2025 followed by net income of $110.1 million in Q1 2026, making it difficult to predict future profitability. Additionally, 95% of revenue is concentrated in North America, and the business relies on third-party co-packers and PepsiCo for distribution, creating operational dependencies that could disrupt supply or sales. The debt-to-equity ratio of 0.228 is low, but the company's return on equity is only 3.67%, indicating inefficient use of capital.
Market and competitive risks are heightened by the stock's premium valuation relative to its growth prospects. The forward PE of 16.33x may appear low, but it is based on aggressive EPS estimates of $2.19, which require flawless execution. The stock's beta of 0.922 suggests lower volatility than the market, but the recent 18% single-day drop on Q2 earnings shows event-driven risk. Competition from Monster Beverage and other energy drink brands is intensifying, and PepsiCo's own North America volume declines could lead to reduced shelf space for Celsius. Regulatory risks, such as potential labeling or ingredient regulations, could also impact the energy drink sector. The stock has underperformed the S&P 500 by 53.02% YTD, and sector rotation away from consumer staples could further pressure the shares.
The worst-case scenario involves a continued decline in flagship Celsius brand sales, failure to achieve the forward EPS estimate of $2.19, and a breakdown below the 52-week low of $23.56. If the company misses earnings again and analysts downgrade the stock, the shares could fall to the analyst low target of $26.00, representing a 7.2% decline from the current price of $28.02. In a more severe scenario, if the stock breaches the 52-week low of $23.56, it could test the $20 level, implying a 28.6% loss from current levels. The maximum drawdown of -63.35% from the peak illustrates the potential severity of a bear market in this stock. Investors could lose 7% to 29% in an adverse scenario, with the risk of further downside if fundamentals deteriorate.
FAQ
The key risks of holding CELH include: 1) Financial risk: Gross margin compression from 52.35% to 48.31% and earnings volatility, with a net loss of -$61.0 million in Q3 2025. 2) Competitive risk: Intense competition from Monster Beverage and other energy drink brands, plus reliance on PepsiCo for distribution, which could be disrupted if PepsiCo's own volumes decline. 3) Macro risk: The stock has a beta of 0.922, but consumer spending on premium beverages could weaken in an economic downturn. 4) Company-specific risk: Declining flagship Celsius brand sales and the risk that the forward EPS estimate of $2.19 is not achieved. The most severe risk is a breakdown below the 52-week low of $23.56, which could lead to further losses.
The 12-month forecast for CELH includes three scenarios: Bull case (25% probability) with a target range of $50-$64, assuming successful Alani Nu integration and margin recovery; Base case (50% probability) with a target range of $35-$45, assuming moderate growth and EPS meeting the $2.19 estimate; and Bear case (25% probability) with a target range of $23.56-$26, assuming continued flagship decline and earnings miss. The base case is most likely, with a target around the analyst average of $42.29. The key assumption is that revenue growth remains above 20% and gross margins stabilize. If the company fails to meet these expectations, the stock could fall to the bear case target.
CELH appears undervalued on a forward basis but fairly valued when considering execution risks. The forward PE of 16.33x is a discount to the consumer defensive sector average of 20-25x, and the price-to-sales ratio of 4.28x is well below its historical average of 54.01x in Q1 2024. However, the trailing PE of 182.96x is extremely high due to depressed earnings, and the PEG ratio is negative. The market is pricing in a significant earnings recovery, with EPS expected to grow from $0.01 to $2.19. If the company achieves this, the stock is undervalued; if it falls short, the current valuation could be too high. Relative to its own history, the stock is cheap, but relative to peers, it is fairly valued given its smaller scale and execution risks.
CELH is a high-risk, high-reward stock that may be a good buy for investors with a high risk tolerance and a long-term horizon. The stock trades at a forward PE of 16.33x, which is below the sector average, and analysts have a consensus buy rating with an average target of $42.29, implying 50.9% upside. However, the company faces significant challenges, including declining flagship brand sales, gross margin compression, and a recent earnings miss that caused an 18% single-day drop. The biggest downside risk is a break below the 52-week low of $23.56, which would represent a 16% loss from the current price. For investors who believe in the Alani Nu growth story and can stomach volatility, the risk/reward may be favorable, but it is not a suitable investment for conservative portfolios.
CELH is more suitable for long-term investment than short-term trading, but it requires a high risk tolerance. The company is in a growth stage, with revenue expanding rapidly but earnings volatile. The beta of 0.922 suggests lower volatility than the market, but the stock has experienced a maximum drawdown of -63.35%, indicating significant risk. The dividend yield is negligible at 0.35%, so returns depend entirely on capital appreciation. Earnings visibility is low due to acquisition integration and competitive pressures. A suggested minimum holding period is 2-3 years to allow for the Alani Nu integration to mature and for the flagship brand to stabilize. Short-term trading is risky due to event-driven volatility, as seen in the 18% single-day drop.